



Creating
drugs at the
speed of AI.

abs-ci®

```
from abs-ci import de_novo_model
model = de_novo_model.load_latest()
antigen = model.load_pdb("7olz.pdb",
chain="A")
antibodies = model.predict(antigen, N=300000)
```

```
from abs-ci_library import codon_optimizer
library
= codon_optimizer.reverse_translate(library)
library.to_csv("covid-antibody-designs.csv")
library.to_wet_lab(assay="ACE")
```

```
from abs-ci import lead_opt_model
lead_optimizer = lead_opt_model.load_latest()
library.naturalness =
lead_optimizer.naturalness(library)
lead_optimizer.optimize(library).to_wet_lab(as
say="SPR")
```

DRUG CREATION



41ST ANNUAL J.P. MORGAN
HEALTHCARE CONFERENCE

2005: 20 approved, 11.2% of drugs entering clinical trials approved 2006: 22 approved, 11.2% 2007: 18 approved, 10.7% 2008: 24 approved, 9.2% 2009:
26 approved, 7.8% 2010: 21 approved, 6.8% 2011: 35 approved, 6.1% 2012: 39 approved, 5.3% 2013: 27 approved, 5.2% 2014: 41 approved, 6.7% 2015: 45
approved, 13.8%

Oxford Academic

Disclaimers





Forward-Looking Statements

Certain statements in this presentation that are not historical facts are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words “will,” “may,” “anticipates,” “plans,” “believes,” “forecast,” “estimates,” “expects,” “predicts,” “advancing,” “aim,” and “intends,” or similar expressions. We intend these forward-looking statements, including statements regarding our strategy, financial performance and results of operations, including our expectations and guidance regarding cash, cash equivalents and restricted cash, our projected cash usage, needs and runway, future operations, future financial position, future revenue, internal research and technological development activities, advancements toward in silico drug design, research and technology development collaboration efforts, growth plans, projected costs, prospects, plans and objectives of management, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncertainties relating to the development of our technology, our ability to secure milestone payments and royalties, and our ability to effectively collaborate on research, drug discovery and development activities with our partners or potential partners; along with those risks set forth in our most recent periodic report filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.



Market and Statistical Information

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other industry data. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified the data generated by independent parties and cannot guarantee their accuracy or completeness.

Trademark usage

This presentation/document/webpage contains references to our trademarks and service marks and to those belonging to third parties. Absci®, **absci.**, SoluPro® and SoluPure® are Absci registered trademarks with the U.S. Patent and Trademark Office. We also use various other trademarks, service marks and trade names in our business, including the Absci logo mark () , the Absci AI logo mark () , the Unlimit with us mark () , the unlimit symbol () , Bionic protein, Bionic Enzyme, Bionic Antibody, Bionic SoluPro, Denovium, Denovium Engine, Drug Creation, Integrated Drug Creation, HiPrBind, HiPrBind Assay, Translating Ideas into Drugs, Translating Ideas into Impact, We Translate Ideas into Drugs, and We Translate Ideas into Impact. All other trademarks, service marks or trade names referred to in this presentation/document/webpage are the property of their respective owners. Solely for convenience, the trademarks and trade names in this presentation/document/webpage may be referred to with or without the trademark symbols, but references which omit the symbols should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

What if the next transformative drug was not discovered but created with a click of a button?




DALL-E generated image of Penelope (Absci's Chief Morale Officer) discovering biologics on a computer.

The Problem—The Need For Generative AI

The old drug discovery paradigm is ripe for disruption

5.5 YEARS FROM
DISCOVERY TO IND

<5% SUCCESS RATE FROM
DISCOVERY TO LAUNCH




Long iterative process creating drug candidates with suboptimal attributes

Why Hasn't Generative AI Transformed Biologic Drug Discovery?


Unlocking the potential of generative AI in biology require scalable biological data

Small molecule




Extensive Libraries

v. Biologic




Limited Data

Biologics requires living organisms to make every drug variant for testing



Consistency and accurate data is limited

Unlocking the potential of generative AI in biology...



...requires generating scalable biological data





Absci is **solving** the problem of scalable biological data enabling **true generative AI** for biologics drug discovery

Absci's *E.coli* SoluPro™ cell line

Billions of cells, expressing proteins-of-interest

Absci's ACE Assay screens billions of unique drug variant candidates

High-quality data flows into Absci's generative AI engine



● NON-BINDING
● TIGHT BINDING



The Solution

At Absci, the future is **now** with our Integrated Drug Creation™ platform

DATA TO TRAIN


Proprietary wet-lab assays capable of generating **billions** of protein-protein interactions a week for ML training

WET LAB TO VALIDATE

Scalable wet-lab infrastructure capable of validating **2.8 million unique** AI-generated designs a week

AI TO CREATE

Generative AI engine to create new antibodies and next-gen biologics



Absci is the Leader in Generative AI Drug Creation for Biologics

Cycles completed within **weeks**




Absci's rapid cycle times aims to:

DATA TO
TRAIN

Typical 6-week per cycle

WET LAB TO
VALIDATE



AI TO CREATE

01

Rapidly iterate
and improve AI
models

02

Reduce preclinical
development
timelines and
increase clinical
PoS

03


Accelerate
Industry progress
and attract top AI
talent



Absci is the **first** to
design and validate
new antibodies with
zero-shot
generative AI

Breakthrough in *de novo* Drug Creation

De novo drug creation with ‘zero-shot’ generative AI



- Zero-Shot: Model has never seen an antibody that binds to the target or homologs
- Binders were identified **straight out of the model** - no lead optimization was performed
- **Demonstrated** across **four therapeutic** targets: HER2, VEGF-A, COVID omicron, undisclosed target

Case Study: *de novo* Discovery in silico

Unlocking *de novo* antibody design with generative AI

Unlocking *de novo* antibody design with generative artificial intelligence

Amir Shanehsazzadeh*, Sharrol Bachas*, George Kasun, John M. Sutton, Andrea K. Steiger, Richard Shuai, Christa Kohnert, Alex Morehead, Amber Brown, Chelsea Chung, Brenna Luton, Nicolas Diaz, Matt McParillon, Bailey Knight, Macey Radach, Katherine Bateman, David A. Spencer, Jovan Cejovic, Gaelin Kopec-Belliveau, Robel Haile, Edriss Yassine, Cailen McCloskey, Monica Natividad, Dalton Chapman, Luka Stojanovic, Rodante Cagliati, Shaheed Abdulhaqq, Zheyuan Guo, Katherine Moran, Lillian R. Klug, Miles Gander, Joshua Meier[§]


AbSci Corporation, New York (NY) and Vancouver (WA), USA

* Equal contribution

§ Corresponding author (jmeier@absci.com)

Abstract

Generative artificial intelligence (AI) has the potential to greatly increase the speed, quality and controllability of antibody design. Traditional *de novo* antibody discovery requires time and resource intensive screening of large immune or synthetic libraries. These methods also offer little control over the output sequences, which can result in lead candidates with sub-optimal binding and poor developability attributes. Several groups have introduced models for generative antibody design with promising *in silico* evidence [1–10], however, no such method has demonstrated *de novo* antibody design with experimental validation. Here we use generative deep learning models to *de novo* design antibodies against three distinct targets in a *zero-shot* fashion where all designs are the result of a single round of model generations with no follow-up optimization. In particular, we screen over 400,000 antibody variants designed for binding to human epidermal growth factor receptor 2 (HER2) [11] using our high-throughput wet lab capabilities. From these screens, we further characterize 421 binders biophysically using surface plasmon resonance (SPR), finding three that bind tighter than the therapeutic antibody trastuzumab [12]. The binders are highly diverse and have low sequence identity to known antibodies. Additionally, these binders score highly on our previously introduced *Naturalness* metric [13], indicating that they are likely to possess desirable developability profiles and low immunogenicity. We open source the binders to HER2 and report the measured binding affinities. These results unlock a path to accelerated drug creation for novel therapeutic targets using generative AI combined with high throughput experimentation.



Case Study: *de novo* Discovery in silico

AI Model generated **highly diverse** and **effective** binders from **massive** search space


SIZE OF
SEARCH SPACE:

MILLIONS

BILLIONS

TRILLIONS

QUADRILLIONS



AI-Designed & **Wet Lab Validated** HER2 Binders

- Hundreds of binders created
- Ability to generate binders near to and far from trastuzumab
- Binding affinity maintained even when mutating >90% of the CDR3 region
- All binders to HER2 and HER2 homologs removed from the training dataset

Case Study: *de novo* Discovery in silico

AI model is broadly applicable enabling higher potential therapeutics


Better therapeutics, faster

- Successfully designed antibody variants with higher Naturalness score
- The Naturalness score is associated with developability metrics such as immunogenicity





Model is validated and broadly applicable

- Successfully demonstrated across four therapeutic targets: HER2, VEGF-A, COVID omicron, undisclosed target

Rapid progress towards fully *in silico* drug creation




Unlocking new and differentiated value drivers

Higher Potential Biologics with Increased PoS	Reducing Time & Increasing Competitiveness	Increasing Options for Personalized Medicine	Broadening Intellectual Property Space
<p>Multidimensional optimization in parallel creates higher quality biologics with an increased Probability of Success</p>  <p>41ST ANNUAL J.P. MORGAN HEALTH CARE CONFERENCE ABSCI CORPORATION 2023 ALL RIGHTS RESERVED</p>	<p>Drug creation process is significantly shortened, reducing research costs and increasing competitiveness</p> 	<p>Specific Epitope targeting increases options for personalized medicine</p> 	<p>AI-driven drug creation generates valuable Intellectual Property</p>  <p>absci 15</p>

Better Biologics Faster

Accelerating time to clinic while increasing PoS



Partnerships

Technology **validated** through industry-leading partnerships



BioSpace

“Merck leans into AI with \$610M in biobucks for Absci drug discovery pact”

*“At Merck we are continually evaluating new ways to build, expand, and refine our biologics capabilities. Absci’s platform offers a compelling opportunity to design new biologic candidates and explore the expression of complex proteins.”**

Dr. Fiona Marshall

Former SVP, Head of Discovery,
Preclinical and Translational Medicine



“EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs”

“Absci’s technology platform enables rapid discovery and production of well-differentiated protein-based drugs that are elusive to other discovery approaches. We are excited to work with Absci...”

Dr. Carlos Garcia-Echeverria

Chief of Rx Creation

Well positioned to revolutionize AI drug creation



* Active Programs: programs in which we have negotiated, or expect to negotiate, license agreements for downstream milestones and royalties. Count as of 9/30/22 10Q filing.

**Unaudited Cash and cash equivalents and short-term investments

41ST ANNUAL J.P. MORGAN HEALTH CARE CONFERENCE | ABSCI CORPORATION 2023 ALL RIGHTS RESERVED

>200

Unlimiters with deep experience in AI, immunology, synthetic biology, and protein expression

**77,000
Square Feet**

State-of-the-art drug creation and wet lab space in Vancouver WA, with Absci AI Research (AAIR) lab in NYC, and Innovation Centre in Zug Switzerland

17

Active Programs* with leading partners

>\$160M

Strong cash position with >\$160M at end of '22**

>200

Patents filed worldwide with dozens more expected in 2023

Billions

High quality high-throughput protein-protein interaction data can be generated a week

Trailblazing Management Team

The right leadership team to accomplish the Impossible

Executive Leadership



SEAN MCCLAIN
Founder & CEO Director

ANDREAS BUSCH, PHD
Chief Innovation Officer

GREG SCHIFFMAN, CPA
Chief Financial Officer

SARAH KORMAN, PHD, JD
Chief Legal Officer

DENISE DETTORE
Chief People Officer

JACK GOLD
Chief Marketing Officer

PENELOPE
Chief Morale Officer

Board of Directors



IVANA MAGOVCEVIC-
LIEBISCH, PhD, JD
CEO & President, Vigil
Neuroscience

ZACH JONASSON, PhD
Managing Partner,
PVP

KAREN MCGINNIS, CPA
Former CAO,
Illumina

AMRIT NAGPAL
Managing Director,
Redmile Group


JOSEPH SIROSH, PhD
Vice President,
Alexa Shopping, Amazon

DAN RABINOVITSJ
VP Connectivity,
Meta

Leadership
experience from:



Absci is leading the way in AI drug creation towards breakthrough therapeutics at the click of a button



absci®



This **revolution** is
only just beginning.